Correction to "Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination" [The Lancet Regional Health - Europe 38 (2024) 100829]

David Hodgson¹, Neil Wilkins², Edwin van Leeuwen^{1

2}, Conall H Watson², Jonathan Crofts², Stefan Flasche¹, Mark Jit¹, Katherine E Atkins^{1

3}

Affiliations

¹ Centre of Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK.
² UK Health Security Agency, London, UK.
³ Centre for Global Health, Usher Institute, Edinburgh Medical School, University of Edinburgh, UK.

Published Erratum

David Hodgson et al. Lancet Reg Health Eur. 2024.

. 2024 Sep 11:45:101073.

doi: 10.1016/j.lanepe.2024.101073. eCollection 2024 Oct.

David Hodgson¹, Neil Wilkins², Edwin van Leeuwen^{1

2}, Conall H Watson², Jonathan Crofts², Stefan Flasche¹, Mark Jit¹, Katherine E Atkins^{1

3}

¹ Centre of Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK.
² UK Health Security Agency, London, UK.
³ Centre for Global Health, Usher Institute, Edinburgh Medical School, University of Edinburgh, UK.

Abstract

[This corrects the article DOI: 10.1016/j.lanepe.2023.100829.].

Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination.
Hodgson D, Wilkins N, van Leeuwen E, Watson CH, Crofts J, Flasche S, Jit M, Atkins KE. Hodgson D, et al. Lancet Reg Health Eur. 2024 Jan 8;38:100829. doi: 10.1016/j.lanepe.2023.100829. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38476752 Free PMC article.